These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Compliance with and tolerance of mefloquine and chloroquine + proguanil malaria chemoprophylaxis in French short-term travellers to sub-Saharan Africa. Carme B, Peguet C, Nevez G. Trop Med Int Health; 1997 Oct; 2(10):953-6. PubMed ID: 9357484 [Abstract] [Full Text] [Related]
6. Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis. Hoebe C, de Munter J, Thijs C. Eur J Clin Pharmacol; 1997 Oct; 52(4):269-75. PubMed ID: 9248763 [Abstract] [Full Text] [Related]
7. Use of malaria prevention measures by North American and European travelers to East Africa. Lobel HO, Baker MA, Gras FA, Stennies GM, Meerburg P, Hiemstra E, Parise M, Odero M, Waiyaki P. J Travel Med; 2001 Oct; 8(4):167-72. PubMed ID: 11703900 [Abstract] [Full Text] [Related]
8. Drugs for preventing malaria in travellers. Jacquerioz FA, Croft AM. Cochrane Database Syst Rev; 2009 Oct 07; (4):CD006491. PubMed ID: 19821371 [Abstract] [Full Text] [Related]
11. From the Centers for Disease Control. Recommendations for the prevention of malaria among travelers. JAMA; 1993 Aug 21; 263(20):2729, 2734, 2737 passim. PubMed ID: 2159078 [Abstract] [Full Text] [Related]
13. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. Camus D, Djossou F, Schilthuis HJ, Høgh B, Dutoit E, Malvy D, Roskell NS, Hedgley C, De Boever EH, Miller GB, International Malarone Study Team. Clin Infect Dis; 2004 Jun 15; 38(12):1716-23. PubMed ID: 15227617 [Abstract] [Full Text] [Related]
14. Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial. Croft AM, Clayton TC, World MJ. Trans R Soc Trop Med Hyg; 1997 Jun 15; 91(2):199-203. PubMed ID: 9196769 [Abstract] [Full Text] [Related]
15. [Not more symptoms with mefloquine use than with other drugs in malaria prophylaxis]. Wolters BA, Bosje T, Luinstra-Passchier MJ. Ned Tijdschr Geneeskd; 1997 Feb 15; 141(7):331-4. PubMed ID: 9132607 [Abstract] [Full Text] [Related]
16. Questionnaire-based analysis of atovaquone-proguanil compared with mefloquine in the chemoprophylaxis of malaria in non-immune Japanese travelers. Kato T, Okuda J, Ide D, Amano K, Takei Y, Yamaguchi Y. J Infect Chemother; 2013 Feb 15; 19(1):20-3. PubMed ID: 22740189 [Abstract] [Full Text] [Related]
17. Malaria chemoprophylaxis regimens: a descriptive drug utilization study. Bloechliger M, Schlagenhauf P, Toovey S, Schnetzler G, Tatt I, Tomianovic D, Jick SS, Meier CR. Travel Med Infect Dis; 2014 Feb 15; 12(6 Pt B):718-25. PubMed ID: 24934849 [Abstract] [Full Text] [Related]
18. Side effects of and compliance with malaria prophylaxis in children. Albright TA, Binns HJ, Katz BZ. J Travel Med; 2002 Feb 15; 9(6):289-92. PubMed ID: 12962582 [Abstract] [Full Text] [Related]
19. Post-marketing surveillance: adverse events during long-term use of atovaquone/proguanil for travelers to malaria-endemic countries. Overbosch D. J Travel Med; 2003 May 15; 10 Suppl 1():S16-20; discussion S21-3. PubMed ID: 12737756 [Abstract] [Full Text] [Related]
20. Long-term malaria prophylaxis for travelers. Knobloch J. J Travel Med; 2004 May 15; 11(6):374-8. PubMed ID: 15569575 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]